Table 2 Molecular subclassification of apocrine carcinoma subtypes

From: EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast

Apocrine carcinoma subtype

Molecular phenotype

Pure apocrine carcinoma

HER-2 (20/37, 54%)a

 

Triple negative (17/37, 46%)

 

 Basal-like breast carcinomab (16/17, 94%)

Apocrine-like carcinoma

Luminal (13/17, 76%)

 

Triple negative (3/17, 18%)

 

 Basal-like breast carcinomab (2/3, 67%)

 

HER-2 (1/17, 6%)

  1. aHER-2/neu gene amplification was used as a criterion.
  2. bOn the basis of EGFR protein expression (Nielsen et al29).
Back to article page